The selling is routine in size and comes from planned transactions; no signal of distress. Monitor for follow-up selling or broader C-suite participation. Non-cash derivative exercises are administrative and not economically significant.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 1 $203.21entry
- T+1 · 8mo ago +2.35%α +2.27% · $207.98
- T+5 · 7mo ago −0.10%α −3.87% · $203.00
- T+20 · 7mo ago −4.16%α −13.89% · $194.75
- T+60 · 5mo ago +34.00%α +20.62% · $272.31
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two Natera insiders sold shares in a recent 7-day window, including the President of Clinical Diagnostics and the Chief Legal Officer, realizing $271K in open-market sales. The Executive Chairman also exercised derivatives but those were non-cash transactions with minimal economic impact.
Key Financial Metrics
Key Facts
- President of Clinical Diagnostics, Solomon Moshkevich, sold 1,048 shares for $211K at ~$201/share
- Chief Legal Officer, Daniel Rabinowitz, sold 300 shares for $60K at ~$201/share
- Executive Chairman Matthew Rabinowitz exercised derivatives for 83,416 shares, but $399K of value was non-cash and tax-related
- Total open-market selling by insiders: $271K
- Cluster involves C-suite executives but total value is <0.001% of $29.5B market cap
Financial Impact
$271,000 in open-market insider selling over 7 days
Risk Factors
- Perception risk if media highlights insider sales without context
- Potential for increased scrutiny if selling continues ahead of next earnings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-NTRA-1775264745936 |
Track record
63 reports on NTRA
6 of 9 bullish or bearish reports moved the stock their way by T+1. Best: +6.55% at T+5 after the Oct 2, 2026 report. 6 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $300.44 Now $288.48 −3.98% settles Nov 17
- Nov 10, 20265d ago Insider Cluster Neutral 3/10 Entry $319.82 to $322.94 Now $288.48 −9.80% ▲ +0.98% +1.33% vs SPY
- Nov 10, 20265d ago S-3ASR Neutral 3/10 Entry $319.82 to $322.94 Now $288.48 −9.80% ▲ +0.98% +1.33% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $310.67 to $320.39 Now $288.48 −7.14% ▲ +3.13% +0.76% vs SPY
- Nov 5, 202611d ago 8-K Mixed 6/10 Entry $310.67 to $320.39 Now $288.48 −7.14% ▲ +3.13% +0.76% vs SPY
- Nov 5, 202611d ago SC 13G Neutral 4/10 Entry $363.76 to $310.67 Now $288.48 −20.69% ▼ −14.59% −14.91% vs SPY
- Nov 4, 202611d ago Insider Cluster Neutral 2/10 Entry $363.76 to $310.67 Now $288.48 −20.69% ▼ −14.59% −14.91% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $391.03 to $363.76 Now $288.48 −26.23% ▼ −6.97% −2.56% vs SPY
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $388.63 to $391.03 Now $288.48 −25.77% ▲ +0.62% −1.03% vs SPY
- Nov 2, 202614d ago 144 Neutral 3/10 Entry $388.63 to $391.03 Now $288.48 −25.77% ▲ +0.62% −1.03% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers